| Full Name | Dr Elie A Nehme |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 25 Years |
| Location | 515 Main St, Olean, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306007091 | NPI | - | NPPES |
| 003905 | Other | NY | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0011X | Preventive Medicine - Undersea And Hyperbaric Medicine | 003905 (New York) | Secondary |
| 207R00000X | Internal Medicine | 003905 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Clifton Fine Hospital | Star lake, NY | Hospital |
| White Plains Hospital Center | White plains, NY | Hospital |
| Adena Pike Medical Center | Waverly, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apogee Medical Group, New York, Pc | 4587793294 | 102 |
| East Post Road Medical Services Pc | 6406198506 | 284 |
| Apogee Medical Group Ohio Inc | 8224082292 | 81 |
News Archive
In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 7 days ago
| Entity Name | Olean General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649296781 PECOS PAC ID: 9133111784 Enrollment ID: O20040401001531 |
News Archive
In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 7 days ago
| Entity Name | Clifton-fine Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235184649 PECOS PAC ID: 9739090382 Enrollment ID: O20040511001168 |
News Archive
In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 7 days ago
| Entity Name | Apogee Medical Group, New York, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841520236 PECOS PAC ID: 4587793294 Enrollment ID: O20100518000664 |
News Archive
In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 7 days ago
| Entity Name | East Post Road Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841767274 PECOS PAC ID: 6406198506 Enrollment ID: O20190419000178 |
News Archive
In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 7 days ago
| Entity Name | Hospitalist Services Of Olean Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871266338 PECOS PAC ID: 7810393626 Enrollment ID: O20210902000936 |
News Archive
In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elie A Nehme, MD 112 N Clinton St, Olean, NY 14760-2727 Ph: (716) 240-9407 | Dr Elie A Nehme, MD 515 Main St, Olean, NY 14760 Ph: (716) 375-7317 |
News Archive
In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.
› Verified 7 days ago
Dr. Neha Bansal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 535 Main St, Olean, NY 14760 Phone: 716-372-0141 Fax: 716-372-6421 | |
Arkady Peterman, M.D, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 535 Main St, Olean, NY 14760 Phone: 716-372-0141 Fax: 716-376-2451 | |
Dr. Zafar K Mirza, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2223 W State St, Suite 115, Olean, NY 14760 Phone: 716-372-5601 Fax: 716-372-5616 | |
Dr. Munir Ahmed Salimi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2223 W State St, Suite 114, Olean, NY 14760 Phone: 716-372-8660 Fax: 716-372-8684 | |
Dr. Zia M Sheikh, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2211 W State St, Suite 121, Olean, NY 14760 Phone: 716-372-2355 Fax: 716-372-8682 | |
Dr. Sam Jayanth Samuel, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2223 W State St, Olean, NY 14760 Phone: 716-372-5601 | |
Dr. Christopher Alki Michaeles, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2223 W State St Ste 120, Olean, NY 14760 Phone: 716-710-8266 |